THE JOURNAL / 25 Sep 2026
Saccharomyces boulardii: evidence and safety boundaries
Saccharomyces boulardii is a live yeast studied in specific gastrointestinal settings. Some reviews report reduced antibiotic-associated diarrhoea, but individual trials are not...
Evidence reviewed: 25 September 2026. Research doses describe study methods; they are not personalised dosing instructions.
The short answer
Saccharomyces boulardii is a live yeast studied in specific gastrointestinal settings. Some reviews report reduced antibiotic-associated diarrhoea, but individual trials are not uniformly positive. It is unsuitable for some vulnerable people, including those with central venous catheters or severe immune compromise.
What it is
S. boulardii is a yeast, not a bacterial probiotic. Strain identity, viable count and formulation matter. A product described only by species and milligrams may not provide enough information to compare it with a clinical trial. It should not be treated as a general-purpose gut reset.
How it works: mechanism versus outcome
Researchers investigate interactions with microbes, intestinal barriers and microbial toxins. These mechanisms do not establish treatment of an infection or justify replacing antibiotics. Being a yeast explains why antibacterial and antifungal medicines have different relevance to its use.
Benefits: what the evidence can support
A systematic review found a reduction in antibiotic-associated diarrhoea across included trials, but baseline risk and study setting matter. A later hospital-based randomised trial did not show the same clear benefit. Presenting both prevents a pooled average from becoming a guarantee for every antibiotic course.[1] [2]
Where evidence is mixed or weak
Strains, doses, antibiotic regimens and patient vulnerability differ. Prevention of antibiotic-associated diarrhoea is not the same as treatment of an established infection, IBS or persistent unexplained diarrhoea. A result for a characterised medicinal preparation cannot automatically be transferred to a retail supplement.
Dosage and forms used in research
Trials use specified preparations and report amounts in milligrams, viable organisms or both. There is no universal conversion between milligrams and CFU. Use the exact strain and viable count when evaluating relevance; do not copy a dose from a different product merely because the species name matches.
Timing and duration
Studies often coordinate use with an antibiotic course and sometimes continue afterwards. That does not establish routine indefinite use. Do not delay prescribed treatment, and ask the treating clinician whether this intervention is appropriate for the particular patient and antibiotic regimen.
Side effects and safety
Rare bloodstream yeast infections have been reported. European product-information safety updates identify central venous catheters, critical illness and immune compromise as important exclusions. Yeast allergy is another concern. Severe diarrhoea, dehydration, fever or blood in stools needs medical attention rather than self-treatment with a live yeast.[3]
Medicines and other supplements
Antifungal medicines can inactivate the organism. Immunosuppressive treatment changes the safety assessment, even if it does not represent a simple chemical interaction. Discuss all live microbial products with the clinical team when receiving cancer treatment, transplant care or treatment for serious illness.
Common myths
A probiotic yeast cannot cause infection
Rare invasive infections are the reason for specific precautions in vulnerable patients.
It replaces antibiotics or treats every diarrhoea episode
The research does not establish either claim. The cause and severity of symptoms matter.
Frequently asked questions
Is S. boulardii the same as ordinary probiotics?
It belongs to the broader live-microbial category but is a yeast, with a distinct evidence and safety profile.
Can I take it with an antifungal?
Ask the prescriber. Antifungal treatment is directly relevant to a live yeast preparation, and the underlying illness also matters.
Is it suitable with a central line?
Do not self-use it. Central venous catheters are a recognised safety exclusion in the European product-information update.
Find the relevant ALL TOLD product information
Use the final product label for ingredients, allergens and serving directions. A study of an ingredient is not a trial of an ALL TOLD product or combination. Product links identify the relevant catalogue entries; they do not establish equivalence to a research preparation.
Related research
Browse the Research ingredient index